Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)

NCT ID: NCT01277432

Last Updated: 2015-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3218 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to:

1. Estimate the prevalence of depression in a consecutive cohort of Chinese patients diagnosed with Type 2 Diabetes (T2D) living in areas of China with different socioeconomical affluence
2. Examine patients' awareness of the frequent coexistence of these 2 conditions
3. Analyze the associations between depression and T2D, in particularly the role of metabolic control, socioeconomical status and cognitive-psychological-behavioral factors
4. To document the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese type 2 diabetic patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Overall objectives of this multicentre study are to document;

1. the prevalence and diagnosis rates of depression in type 2 diabetic (T2D) patients attending 7 centres in 4 major cities in China including Hong Kong (HK), Shanghai (SH), Guangzhou (GZ) and Beijing (BJ)
2. the predisposing, precipitating and perpetuating factors for depression and their interrelationships in Chinese T2D patients

This study includes two phases. In the phase I pilot study, the investigators shall confirm and compare the validity of Patient Health Questionnaire (PHQ-9) and Clinical Epidemiological Scale for Depression (CESD) in predicting depression in Chinese T2D patients using the SCID as a gold standard. Other questionaires which measure personal and external factors, diabetes associated distress and anxiety, quality of life, mental wellness, self efficacy, health-related behavior and compliance will also be used to document possible predisposing, precipitating and perpetuating factors for depression in diabetes. These results will be used to select a set of tools which are most informative in the evaluation of depression and mental wellness in T2D patients based on their predictions for health behavior, compliance and metabolic control. A random sample of 100 T2D patients will be recruited from 3 Diabetes Centres in GZ, BJ and HK who will complete a full set of questionnaires and structured clinical assessments using a web-based electronic portal. In each of the three centres, all patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ\>10 and/or CES\>16) and a random sample of 20 subjects with no or mild symptoms will undergo face-to-face interview by psychiatrists using the following instruments: SCID, BDI, SSI-28 (somatization), Coping (Brief Cope 28, Chinese version).

In Phase II, the investigators shall use a subset of the most informative questionaires to document the rates of depression (diagnosed and undiagnosed) and cognitive-psychological-behavioral factors in a consecutive cohort of Chinese patients with T2D and its associations with metabolic control and psychological behavioral factors. In each of the 7 participating centres in HK, SH, BJ and GZ, 500 consecutive patients will undergo comprehensive clinical assessments for risk factors, complications and medications the JADE (Joint Asia Diabetes Evaluation) e-portal, giving a total of 3500 patients.

This survey which documents the rate of depression in T2D patients using similar methodologies will provide a comprehensive data set for exploratory analysis of the multicausality and heterogeneity of clinical presentation and risk factors in Chinese populations. Once this cohort is established and subject to availability of future funding, they can be followed up prospectively to validate and discover risk factors for new onset of depression. Apart from raising awareness, these data are essential in our design of care models and interventions to tailor the unmet needs of these patients. Data from this study will also provide insights into the effects of rapid acculturation and migration on the double burden of diabetes and depression in Chinese populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psychiatrist interview

All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ\>10 and/or CES\>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:

* MINI
* SSI-28 (somatization)

Psychiatrist Interview

Intervention Type OTHER

Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:

* MINI
* SSI-28 (somatization)

Depression screening

All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.

All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.

Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;

1. Patient Health Questionnaire (PHQ-9)
2. Depression Anxiety and Stress Scale (DASS-21)
3. Diabetes Distress Scale (DDS-17)
4. Life events questions (Inter-Heart Study)
5. Diabetes Empowerment Scale (C-DES 20)
6. Summary of Diabetes Self Care Activities (SDSCA-15)
7. Euroqol-5D (EQ-5D)

Depression screening - control

Intervention Type OTHER

All study participants will undergo;

1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal
2. a detailed psychological and behavioral assessments using validated questionnaires
3. several specialist questionnaires on depression, self care and quality of life

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psychiatrist Interview

Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:

* MINI
* SSI-28 (somatization)

Intervention Type OTHER

Depression screening - control

All study participants will undergo;

1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal
2. a detailed psychological and behavioral assessments using validated questionnaires
3. several specialist questionnaires on depression, self care and quality of life

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients diagnosed with type 2 diabetes
2. Aged ≥25 and \<75 years inclusive
3. Chinese ethnicity

Exclusion Criteria

1. Patients with mental/physical handicap and/or difficulty in communication such as deafness, mental retardation
2. Patients with disabling diseases or reduced life expectancy such as severe heart failure, stroke, respiratory diseases, or late stages of cancer
3. Patients diagnosed with type 1 diabetes, defined as presentation with diabetic ketoacidosis or unprovoked ketosis or requirement of continuous insulin requirement within 12 months of diagnosis
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Asia Diabetes Foundation

OTHER

Sponsor Role collaborator

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juliana Chan

Professor Chan

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juliana Chan, MD

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1st Affiliated Hosp, Peking University

Beijing, , China

Site Status

China-Japan Friendship Hospital

Beijing, , China

Site Status

Peking Union Hospital

Beijing, , China

Site Status

Peking University People's Hospital

Beijing, , China

Site Status

Third Affiliated Hospital of Sun Yat-Sen University

Guangzhou, , China

Site Status

Shanghai Sixth People's Hospital

Shanghai, , China

Site Status

YCK Diabetes Assessment Centre, Prince of Wales Hospital

Shatin, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China Hong Kong

Related Links

Access external resources that provide additional context or updates about the study.

http://www.adf.org.hk

Works of the Asia Diabetes Foundation

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRE-2010-281

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Novel Chinese Medicine Formula for Diabetes
NCT06978023 NOT_YET_RECRUITING PHASE2